However, when women used steroid-resembling estrogen drugs in MHT, the risk of ovarian cancer was carefully evaluated because synthesized estrogen analogues possibly bind to ERα and ERβ unequally (32,33). Here, ESR1 is linked to ovarian carcinoma.